Camibirstat

FHD-286 is a selective, oral inhibitor of SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor. FHD-286 has the potential for the research of BAF (BRG1/BRM-associated factor) -related disorders such as acute myeloid leukemia[1].

Product Specifications

CAS Number

[2671128-05-3]

Product Name Alternative

FHD-286

UNSPSC

12352005

Target

Epigenetic Reader Domain; Oxidative Phosphorylation

Type

Reference compound

Related Pathways

Epigenetics; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/fhd-286.html

Purity

99.06

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

COC[C@@H](C(NC1=NC(C2=CC=CC(N3C[C@@H](O[C@@H](C3)C)C)=N2)=CS1)=O)NC(C4=CN(C=C4)S(C)(=O)=O)=O

Molecular Formula

C24H30N6O6S2

Molecular Weight

562.66

References & Citations

[1]Warren C. Fiskus, et al. Abstract 1140: Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPases BRG1 and BRM by FHD-286 in cellular models of AML. Cancer Res (2023) 83 (7_Supplement) : 1140.|[2]Kana Ichikawa, et al. Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models.